Given unveils next-generation Colon Pillcam

Given Imaging has already obtained the EU CE Mark for the Pillcam Colon2.

Endoscopic capsule developer Given Imaging Ltd. (Nasdaq: GIVN; TASE: GIVN) today unveiled its next-generation Pillcam Colon at the Gastro 2009 Conference in London. The Pillcam Colon2 is a development of the Pillcam Colon1, and is aimed at being more patient friendly, as well as providing better visualization of the colon.

The Pillcam Colon2 includes proprietary, innovative technologies, including intelligent functionality and superior imaging, designed to provide physicians with clear and precise views of the colon and polyps of interest.

Given Imaging has already obtained EU CE Mark certification for the Pillcam Colon2 and has begun marketing in select European countries, with continent wide availability planned by mid-2010.

The Pillcam Colon2 has two-way communications to improve the capsule's motion and imaging. The number of images has been increased to 35 frames per second from four frames per second. Advanced optics provides a 172-degree field of view offering a near 360-degree view of the colon.

A comparative study of which PillCam Colon2 to colonoscopy at five hospitals in Israel showed a sensitivity of 89% and a specificity of 76% in detecting polyps six mm or larger, and a sensitivity of 88% and a specificity of 89% in detecting polyps ten mm or larger. The study included 98 patients who had risks or warning symptoms of colon disease.

Given Imaging president and CEO Homi Shamir said, "PillCam Colon2 incorporates the cumulative expertise gained from the first PillCam Colon as well as more than one million PillCam capsule ingestions worldwide. Despite the small size of this initial study and the relatively low prevalence of polyps, we are very encouraged by this data and look forward to working with leading gastroenterologists in Europe, the United States and other markets to initiate additional clinical trials."

Given Imaging also has Pillcams for the small bowel and esophagus.

Given Imaging closed at $16.92 on Nasdaq on Friday, giving a market cap of $495 million, and rose over 4% in premarket trading today. The share rose 4.3% by mid-afternoon on the TASE to NIS 66.93.

Published by Globes [online], Israel business news - www.globes-online.com - on November 23, 2009

© Copyright of Globes Publisher Itonut (1983) Ltd. 2009

5 Comments
View comments in rows
Update by email about comments talkback
POST
Comments
Your name
Please insert your name
Content
Hyperlink in a new window Hyperlink Right Left underline italic bold Bulleted List Ordered List Face1 Face2 Face3 Face4 Face5 Face6
Your comment

Thanks
You comment was recieved and soon will be published.
In posting comments, I agree to abide by the Terms of Use
Globes encourages lively and frank debate, but posts that the editors consider merely abusive or otherwise inappropriate will be removed. Report inappropriate content
Thank you for posting your comment, which will be reviewed for publication.
Loading Comments...load
Load more comments
Yaron Daniely Replacing Ritalin

Alcobra has had two successful Nasdaq offerings this year as it develops an ADHD treatment with fewer side effects.

Twitter Facebook Linkedin RSS Newsletters